Search research articles
Contact Us
Filters
Showing results (51-60 of 115) with videos related to
Page
of 12
Sort By:
Gut
|
February 27, 2025
Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies
Ciro Celsa, Grazia Pennisi, Adele Tulone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 22, 2024
Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death
Giuseppe Cabibbo, Ciro Celsa, Salvatore Battaglia, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
August 29, 2024
What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg-negative anti-HBc-positive patients? Meta-analysis and decision curve analysis
Ciro Celsa, Giacomo E M Rizzo, Gabriele Di Maria, et al.
Liver Cancer
|
May 16, 2024
Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis
Ciro Celsa, Giuseppe Cabibbo, David James Pinato, et al.
The Lancet. Gastroenterology & Hepatology
|
September 15, 2025
Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis
Ciro Celsa, Grazia Pennisi, Adele Tulone, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
August 19, 2024
Clinical outcomes of MAFLD versus NAFLD: A meta-analysis of observational studies
Grazia Pennisi, Giuseppe Infantino, Ciro Celsa, et al.
Biomedicines
|
November 11, 2022
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints
Paolo Giuffrida, Ciro Celsa, Michela Antonucci, et al.
Medicine
|
June 3, 2020
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib
Andrea Casadei-Gardini, Vincenzo Dadduzio, Giulia Rovesti, et al.
The Lancet. Oncology
|
July 6, 2023
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept
Alessandro Vitale, Giuseppe Cabibbo, Massimo Iavarone, et al.
JAMA Oncology
|
August 14, 2025
Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis
Ciro Celsa, Gabriele Di Maria, Pasquale Lombardi, et al.
Page
of 12
Search research articles
Search
Showing results (51-60 of 115) with videos related to
Sort By:
Page
of 12
Gut
|
February 27, 2025
Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies
Ciro Celsa, Grazia Pennisi, Adele Tulone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 22, 2024
Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death
Giuseppe Cabibbo, Ciro Celsa, Salvatore Battaglia, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
August 29, 2024
What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg-negative anti-HBc-positive patients? Meta-analysis and decision curve analysis
Ciro Celsa, Giacomo E M Rizzo, Gabriele Di Maria, et al.
Liver Cancer
|
May 16, 2024
Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis
Ciro Celsa, Giuseppe Cabibbo, David James Pinato, et al.
The Lancet. Gastroenterology & Hepatology
|
September 15, 2025
Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis
Ciro Celsa, Grazia Pennisi, Adele Tulone, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
August 19, 2024
Clinical outcomes of MAFLD versus NAFLD: A meta-analysis of observational studies
Grazia Pennisi, Giuseppe Infantino, Ciro Celsa, et al.
Biomedicines
|
November 11, 2022
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints
Paolo Giuffrida, Ciro Celsa, Michela Antonucci, et al.
Medicine
|
June 3, 2020
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib
Andrea Casadei-Gardini, Vincenzo Dadduzio, Giulia Rovesti, et al.
The Lancet. Oncology
|
July 6, 2023
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept
Alessandro Vitale, Giuseppe Cabibbo, Massimo Iavarone, et al.
JAMA Oncology
|
August 14, 2025
Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis
Ciro Celsa, Gabriele Di Maria, Pasquale Lombardi, et al.
Page
of 12